Dr. Ramana Jagarlamudi And Dr. Raghavendra Rao Seen Showcasing Kardi Ai, The AI-Powered Long-Term ECG Monitoring Technology Being Launched In The Indian Market At Hyderabad
Hyderabad, Sept 18: A new generation of AI-powered long-term cardiac monitoring technology is set to enter the Indian market, with the official launch of Kardi Ai scheduled for September 26 in Hyderabad, disclosed Dr. Ramana Jagarlamudi, Director – International Operations & Authorized Representative – India, Kardi Ai, and Dr. Raghavendra Rao, Scientific Adviser & Co-Founder, Eurasia Medical Technologies LLP addressing a press conference in the city on Friday at FTCCI
The launch to open a new chapter in cardiac monitoring. Developed by Kardi Ai, a Czech HealthTech company, the technology combines a wearable ECG chest strap, mobile connectivity and AI-supported ECG analysis to enable long-term heart-rhythm monitoring while patients continue their normal daily lives.
The India launch is being facilitated by Hyderabad-based Eurasia Medical Technologies LLP, the Indian arm of Kardi Ai.
The technology addresses a fundamental challenge in cardiac diagnosis: an irregular heartbeat may not occur when a patient is undergoing a conventional ECG or even during a 24-hour Holter examination.
A conventional ECG provides a short snapshot of the heart, while a Holter monitor typically records cardiac activity for a defined period, often 24 hours. Kardi Ai is designed to extend the monitoring window, enabling doctors to access ECG data collected over a longer period and helping them identify intermittent cardiac rhythm abnormalities that may otherwise go undetected.
From snapshot to long-term observation, it goes a long way in studying the heart functioning more effectively
Explaining the concept simply: ECG is a snapshot of the heart, Holter is a 24-hour recording and Kardi AI is a long-term observation of heart rhythm
The patient wears a lightweight ECG chest strap during everyday activities. The recorded ECG data is transmitted through the mobile platform, while AI-supported analysis assists physicians in reviewing and identifying potential rhythm abnormalities.
The technology is intended to support physicians and does not replace clinical diagnosis or medical decision-making.
Kardi Ai is being introduced in India as a prescription-grade medical technology rather than a consumer fitness device.
According to the company, the device has secured an MD-15 licence from the Government of India for import and sale in India. It is CE marked under the European Union medical-device regulatory framework. It is EU MDR Class IIa classification product.
Manufacturing/quality processes it is aligned with ISO 13485, the international quality-management standard for medical devices
The official launch will bring together cardiologists, electrophysiologists, physicians, hospital leadership, healthcare technology professionals and other stakeholders to discuss the future of long-term rhythm monitoring, remote cardiac care and AI-supported ECG analysis.
The launch programme will feature clinical sessions on cardiac arrhythmias, detection and diagnosis, the clinical value of long-term ECG monitoring, and Kardi Ai’s application in clinical practice, followed by a panel discussion and official launch.
The launch will be held on Saturday, September 26, 2026, from 6:30 PM onwards at Daspalla Hotel, Jubilee Hills, Hyderabad.
With cardiovascular diseases continuing to require early detection and sustained monitoring, the India launch of Kardi Ai comes at a time when healthcare is increasingly moving towards remote monitoring, digital health and AI-assisted clinical decision support.
The central proposition is simple: when an abnormal rhythm is intermittent, a longer window of observation can provide doctors with more information than a short snapshot.
“From signal to insight for healthier lives” is the theme of the India launch, which seeks to explore how long-term ECG monitoring, remote cardiac care and artificial intelligence can contribute to the future of cardiovascular healthcare in India.
“Cardiovascular disease remains India’s leading cause of death, making early detection and continuous monitoring of cardiac abnormalities an increasingly important healthcare priority. WHO estimates that around 220 million Indians live with hypertension, one of the country’s major cardiovascular risk factors, while only about 12% have their blood pressure under control.”
“Against this backdrop, Kardi Ai is introducing an AI-powered long-term ECG monitoring system designed to give physicians a longer window into a patient’s heart rhythm—particularly when abnormalities may be intermittent and therefore missed during a short ECG or a conventional 24-hour Holter.”
Leave a Reply